New York, NY - February 24, 2012 - (Investorideas.com Newswire) Investorideas.com, a leader in research for independent investors presents an investor snapshot of Homeland Security and Biodefense stocks , PositiveIDCorporation (OTCBB: PSID) and Northrop Grumman (NYSE: NOC), two potentially qualified biodetector systems suppliers for BioWatch Gen-3.
The Department of Homeland Security Office of Procurement Operations anticipates soliciting final Phase II RFP for the first or second quarter of FY 2012.The Gen-3 detection system will be a fully autonomous network of biodetectors that will continuously monitor the air for biothreat agents.
In a recent interview with Investorideas.com. Mr. William J. Caragol, Chairman and Chief Executive Officer of PositiveIDCorporation (OTCBB: PSID) noted, "Our MicroFluidic Systems ("MFS") subsidiary, is a leader in biothreat detection technologies and molecular diagnostic systems, and developed its M-BAND technology under contract from DHS over the past eight years. We believe our M-BAND, a Microfluidics-based Bioagent Autonomous Networked Detector, is one of only two technologies that is compatible with DHS' procurement for Gen-3 of Biowatch, which has a total value of more than $3 billion over approximately five years, as described by the DHS in their draft RFP. This opportunity, relative to the provision of biodetectors and the renewables, represents a very significant opportunity for PositiveID. "
PositiveID Corporation (OTCBB: PSID) announced it will present its M-BAND (Microfluidics-based Bioagent Autonomous Networked Detector) system at the 10th Annual American Society for Microbiology ("ASM") Biodefense and Emerging Diseases Research Meeting, to be held February 26-29, 2012, in Washington, DC at the Omni Shoreham Hotel. PositiveID will jointly exhibit M-BAND with The Boeing Company and Hamilton Sundstrand.
Northrop Grumman's (NYSE: NOC) biodefense division will be a key player in Biowatch as it moves forward, with previous contracts announced back in 2010. Northrop delivered critical assay technology to DHS as part of the company's BioWatch Gen-3 contract .The assay represents the key technological component of Northrop Grumman's BioWatch Gen-3 system.
According to the company's press release, Northrop Grumman's Advanced Concepts & Technologies Division is providing its Next-Gen Automated Detection Systems (NG-ADS) for independent laboratory and field testing at military and national laboratories.
"Automating the bio-detection process in these next generation instruments will provide much earlier warning of a bio-terrorism attack," said Dave Tilles, vice president of homeland defense programs at Northrop Grumman. "It will operate 24 hours per day, 365 days per year, in select cities across the nation. Earlier warning will allow the nation's public health and safety officials to reduce exposure, distribute medication sooner and proactively manage the response to a bio-threat."
As the RFP for Biowatch moves forward in 2012, investors can follow the money flow from DHS as qualified biodetector systems are contracted and deployed.
More info on Biowatch; follow the updates:
Learn more about PSID at Investorideas.com
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Get Free investor news and stock alerts
Sign Up: http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure: Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. PositiveID Corporation ( OTCBB:PSID ) featured biotech company on Investorideas.com for 3 months effective January 30, 2012. Compensation: two hundred fifty thousand 144 shares for news release publication, syndication on blogs and related sites and email distribution and company profile . More info: www.InvestorIdeas.com/About/Disclaimer.asp and disclosures: http://www.investorideas.com/About/News/Clientspecifics.asp
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Contact Investorideas.com 800 665 0411
PositiveID Corporation (OTCBB:PSID) is a featured biotech company on Investorideas.comVisit the company profile: http://www.investorideas.com/CO/PSID/